Lundbeck peddles meds to Recordati for $100M; Amarin hits another FDA delay on Vascepa;

@FiercePharma: AstraZeneca beats back would-be Crestor copycats. Report | Follow @FiercePharma

> Denmark's Lundbeck said it would sell off a handful of products to Italy's Recordati for $80 million up front and a possible $20 million in additional payments. Report

> The FDA once again delayed its decision on Amarin's ($AMRN) market exclusivity for its blood-lipid drug Vascepa. Report

> Europe's drug-review committee has recommended against approval of Vanda Pharmaceuticals' ($VNDA) antipsychotic drug Fanaptum. Report

> Prominent pediatricians and public health experts warn that banning the vaccine preservative thimerosal would interfere with immunization campaigns in developing countries. Report (sub. req.)

> Mayne Pharma is raising $19 million to fund the acquisition of GlaxoSmithKline's ($GSK) morphine-based pain drug Kapanol. Report (sub. req.)

Medical Device News

 @FierceMedDev: Malaysia is working hard to diversify its med device manufacturing base. International competition is increasing. News | Follow @FierceMedDev

@MarkHFierce: Barron's sees J&J poised for major growth, but NOT through its med device business. More | Follow @MarkHFierce

 @DamianFierce: Quintiles is handling recruitment and "clinical services" for AstraZeneca's novel depression drug. Story | Follow @DamianFierce

> Orthofix resolves Medicare kickback case. News

> Amarantus licenses Alzheimer's blood Dx. Story

> Bioresorbable stents hit India, but most patients can't afford them. Article

Biotech News

 @FierceBiotech: Baxter joins Big Pharma funds on $38M B round for Naurex antidepression R&D. Article | Follow @FierceBiotech

@JohnCFierce: Troubled Intercell (bought Iomai) throws in the towel, signs off on merger deal with Vivalis. More | Follow @JohnCFierce

@RyanMFierce: Dang. Another biotech deal this busy am. Naurex nails down $38M B round led by Baxter for depression candidate. Release | Follow @RyanMFierce

> Tranzyme takes a beating after scuttling another drug study. Report

> Apple Tree inks $305M drug deal to back biotech portfolio game plan. News

> Phenex grabs $135M discovery deal with J&J. Item

Biotech IT News

> How lessons from iPhone's Siri aid biological exploration. Story

> GlaxoSmithKline dials up Vodafone for mobile tech alliance. Article

> Russian billionaire backs 23andMe in $50M round. News

> Could computers predict the next big Alzheimer's drug? Report

CRO News

> Patheon closes $255M Banner deal. Item

> Charles River projects a modest 2013, slides on the Street. Story

> Catalent inks biosimilar deal with Japanese CMO. Article

> Quintiles recruiting for AstraZeneca's novel depression drug. News

> Warnex closes bioanalytics sale, exits CRO biz. Report

And Finally... A longtime proponent of opioid painkillers is backpedaling on early recommendations as new research suggests a higher risk of addiction than previously thought. Report (sub. req.)